The Oncology Drug Development Process
Jo Anne Zujewski, MD, head, breast cancer therapeutics, cancer therapy evaluation program, National Cancer Institute, discusses the FDA approval process for oncology drugs.
Jo Anne Zujewski, MD, head, breast cancer therapeutics, cancer therapy evaluation program, National Cancer Institute, discusses the FDA approval process for oncology drugs.
Patients want "more, better, faster" in regards to FDA-approved oncology drugs, Zujewski says.Any delay is a disadvantage to patients. Zujewski says she is in favor of international collaborations and standardization of information to ease the process.
Clinical Pearls
Some advances that have been made have been in part due to retrospectively-collected data sets. Going forward, Zujewski says, trials should be developed that have the capacity for retrospective data collection so that, with diagnostic developers, the timeline for approval can be accelerated.
- Any approval delay is a disadvantage to patients
- International collaborations and standardization of information and data can aid the process
- Retrospectively collected data sets can help a drug to advance
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
